TY - JOUR
T1 - Designing Clinical Trials to Assess the Impact of Pharmacological Treatment for Suicidal Ideation/Behavior
T2 - Issues and Potential Solutions
AU - Yao, Zhixing
AU - McCall, William V.
N1 - Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer Nature Switzerland AG.
PY - 2023/5
Y1 - 2023/5
N2 - Suicide is a serious and growing public health concern yet randomized controlled trials (RCTs) that inform pharmacologic treatment remain limited. We emphasize the overall need for such trials and review the literature to highlight examples of trials that have aimed to study patients at elevated risk of suicide. We discuss key examples of existing psychotropic medication trials as well as psychotherapy intervention studies that can yield important design insights. Medications that have been studied in individuals at risk for suicide include lithium, clozapine, zolpidem, prazosin, ketamine, esketamine, and aripiprazole. While important design challenges should be considered—RCTs to study suicide are feasible and much needed. Issues such as overall trial design, patient-selection criteria, and the scales/tools used to assess suicidality are discussed.
AB - Suicide is a serious and growing public health concern yet randomized controlled trials (RCTs) that inform pharmacologic treatment remain limited. We emphasize the overall need for such trials and review the literature to highlight examples of trials that have aimed to study patients at elevated risk of suicide. We discuss key examples of existing psychotropic medication trials as well as psychotherapy intervention studies that can yield important design insights. Medications that have been studied in individuals at risk for suicide include lithium, clozapine, zolpidem, prazosin, ketamine, esketamine, and aripiprazole. While important design challenges should be considered—RCTs to study suicide are feasible and much needed. Issues such as overall trial design, patient-selection criteria, and the scales/tools used to assess suicidality are discussed.
UR - http://www.scopus.com/inward/record.url?scp=85152440307&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85152440307&partnerID=8YFLogxK
U2 - 10.1007/s40290-023-00467-x
DO - 10.1007/s40290-023-00467-x
M3 - Review article
C2 - 37046135
AN - SCOPUS:85152440307
SN - 1178-2595
VL - 37
SP - 221
EP - 232
JO - Pharmaceutical Medicine
JF - Pharmaceutical Medicine
IS - 3
ER -